Similar articles

• Part II. Eosinophilia-Myalgia Syndrome: further correlations between compromised histamine degradation, eosinophilias and myopathies.

  Smith MJ, Garrett RH. Smith MJ, et al. Inflamm Res. 2007 Apr;56 Suppl 1:S7-8. doi: 10.1007/s00011-006-0503-0. Inflamm Res. 2007. PMID: 17806156 No abstract available.
• Antineutrophil cytoplasmic antibodies and the eosinophilia myalgia syndrome.

  Schnabel A, Gross WL, Berg PA, Klein R, Lehnert H. Schnabel A, et al. Ann Rheum Dis. 1995 Mar;54(3):233. doi: 10.1136/ard.54.3.233-a. Ann Rheum Dis. 1995. PMID: 7748023 Free PMC article. No abstract available.
• Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.

  Villanova M, De Clerck LS, Cras P, Guazzi GC, Martin JJ. Villanova M, et al. Acta Neurol Belg. 1994;94(3):200-4. Acta Neurol Belg. 1994. PMID: 7976226
• The cause and pathogenesis of the eosinophilia-myalgia syndrome.

  Varga J, Uitto J, Jimenez SA. Varga J, et al. Ann Intern Med. 1992 Jan 15;116(2):140-7. doi: 10.7326/0003-4819-116-2-140. Ann Intern Med. 1992. PMID: 1727618 Review.
• Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.

  Silver RM. Silver RM. Curr Opin Rheumatol. 1992 Dec;4(6):851-6. Curr Opin Rheumatol. 1992. PMID: 1457280 Review.